Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics (ELVN) Form 144 notice shows a proposed sale of 12,500 common shares through Jefferies with an aggregate market value of $249,125, with an approximate sale date of 09/19/2025. The filer states these shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filing reports 59,000,000 shares outstanding for the issuer.
The filing also discloses recent insider transactions: 24,500 shares sold by Joseph Lyssikatos during July–August 2025 for total gross proceeds of $526,862.01 across three transactions. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Form 144 notice filed for Enliven Therapeutics (ELVN) by a holder reporting proposed and recent sales of common stock. The filer indicates a proposed sale of 12,500 shares through Jefferies LLC with an aggregate market value of $230,375.00, and reports that the shares were originally acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filing also discloses sales by the same person totaling 25,000 shares during the past three months, producing gross proceeds of $531,767.21. The issuer has 59,000,000 shares outstanding and the proposed sale is scheduled approximately for 09/17/2025. The filer certifies no undisclosed material adverse information and includes standard Rule 144 representations.